Progress in Nanotechnology-Enabled Drug Delivery for Glioblastoma: Reports Since 2020
نویسندگان
1 Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Basic Science, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
doi
10.22034/nmrj.2025.02.004چکیده
Glioblastoma (GBM) is the highest aggressive primary brain malignancy, with a median overall survival of only ~15 months despite maximal surgical resection followed by radiotherapy and chemotherapy. A major obstacle to effective treatment is the blood–brain barrier (BBB), which significantly prevents the intracranial delivery of most therapeutics. In this review, we first outline the advantages of using nanoparticle (NPs) in GBM treatment. We then critically examine recent advances in various types of NPs designed to traverse the BBB and enhance drug accumulation in GBM. Finally, we summarize ongoing clinical trials involving NP-enabled therapies and discuss emerging design principles and future research directions necessary to translate these platforms into clinical practice. By addressing the challenges of targeted delivery and controlled release, these innovative nanoplatforms hold promise to improve therapeutic efficacy and reduce systemic toxicity, ultimately aiming to extend survival and quality of life for GBM patients.
